GIUNCHI, VALENTINA

GIUNCHI, VALENTINA  

DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE  

Dottorandi  

Mostra records
Risultati 1 - 12 di 12 (tempo di esecuzione: 0.025 secondi).
Titolo Autore(i) Anno Periodico Editore Tipo File
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System Raschi E.; Fusaroli M.; Giunchi V.; Repaci A.; Pelusi C.; Mollica V.; Massari F.; Ardizzoni A.; P...oluzzi E.; Pagotto U.; Di Dalmazi G. 2022-01-01 CANCERS - 1.01 Articolo in rivista cancers-14-04610-v2 (2).pdf
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors Sisi, Monia; Vitale, Giovanni; Fusaroli, Michele; Riefolo, Mattia; Giunchi, Valentina; D’Errico, ...Antonietta; Ardizzoni, Andrea; Raschi, Emanuel; Gelsomino, Francesco 2023-01-01 JTO CLINICAL AND RESEARCH REPORTS - 1.01 Articolo in rivista -
Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach Giunchi, Valentina; Fusaroli, Michele; Hauben, Manfred; Raschi, Emanuel; Poluzzi, Elisabetta 2023-01-01 DRUG SAFETY - 1.01 Articolo in rivista -
Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System Fusaroli M.; Pelletti G.; Giunchi V.; Pugliese C.; Bartolucci M.; Necibi E.N.; Raschi E.; De Pont...i F.; Pelotti S.; Poluzzi E. 2023-01-01 DRUG SAFETY - 1.01 Articolo in rivista s40264-022-01269-x.pdf40264_2022_1269_MOESM1_ESM.pdf
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS Fusaroli M.; Giunchi V.; Battini V.; Puligheddu S.; Khouri C.; Carnovale C.; Raschi E.; Poluzzi E. 2024-01-01 DRUG SAFETY - 1.01 Articolo in rivista s40264-023-01391-4.pdf40264_2023_1391_MOESM1_ESM.docx
Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study Fusaroli M.; Giunchi V.; Battini V.; Gringeri M.; Rimondini R.; Menchetti M.; Radice S.; Pozzi M....; Nobile M.; Clementi E.; De Ponti F.; Carnovale C.; Raschi E.; Poluzzi E. 2023-01-01 PSYCHIATRY AND CLINICAL NEUROSCIENCES - 1.01 Articolo in rivista Exploring the underlying mechanisms of drug-induced impulse control disorders a pharmacovigilance-pharmacodynamic study.pdf
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System Fusaroli M.; Raschi E.; Giunchi V.; Menchetti M.; Rimondini Giorgini R.; De Ponti F.; Poluzzi E. 2022-01-01 INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY - 1.01 Articolo in rivista pyac031-10.pdfpyac031_suppl_supplementary_material.pdf
L’impatto ambientale dei farmaci sulle acque superficiali e la sua stima attraverso i dati di utilizzo Valentina Giunchi 2023-01-01 RECENTI PROGRESSI IN MEDICINA - 1.01 Articolo in rivista -
Post-marketing safety profile of cannabis products: Signals from the FDA adverse event reporting system Giunchi, V; Fusaroli, M; Lunghi, C; Zongo, A; Raschi, E; Poluzzi, E 2022-01-01 PHARMACOEPIDEMIOLOGY AND DRUG SAFETY - 1.06 Abstract in rivista -
Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People Lunghi C.; Trevisan C.; Fusaroli M.; Giunchi V.; Raschi E.; Sangiorgi E.; Domenicali M.; Volpato ...S.; De Ponti F.; Poluzzi E. 2022-01-01 PHARMACEUTICALS - 1.01 Articolo in rivista Lunghi-Trevisan 2022 Pharmaceuticals.pdf
The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water supplies Giunchi V.; Fusaroli M.; Linder E.; Villén J.; Wettermark B.; Nekoro M.; Raschi E.; Lunghi C.; Po...luzzi E. 2023-01-01 BRITISH JOURNAL OF CLINICAL PHARMACOLOGY - 1.01 Articolo in rivista Brit J Clinical Pharma - 2023 - Giunchi - The environmental impact of pharmaceuticals in Italy Integrating healthcare and.pdf15761.zip
What Is the Safety Profile of Cannabis-Based Medications? Analysis of the Post-Marketing Signals from the FDA Adverse Event Reporting System Lunghi, C; Fusaroli, M; Giunchi, V; Raschi, E; Zongo, A; Poluzzi, E 2022-01-01 DRUG SAFETY - 1.06 Abstract in rivista -